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ABSTRACT
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the mutant receptor and/or an transcriptional induction of a
nuclear hormone receptor construct. The invention also
relates to a nuclear hormone receptor response element
denoted by the formula YDRXZ comprising a direct repeat

(DR) comprising two half sites separated by X nucleic acid
bases; wherein Z indicates the presence of at least one DR
oriented in either a forward or reverse orientation; wherein

Y equals 1 to 8 forward and/or reverse direct repeats; and X
equals 1 to about 12.
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MUTANTS AND ASSAY SYSTEM TO
IDENTIFY USP/RXR LIGANDS

et al., Annual RevieW of Entomology, 43:545-569 (1998);
Harmon et al. Proc Natl. Acad. Sci. USA., 92:6157-6160

(1 995).
This speci?cation claims the bene?t of and incorporates
by reference US. Provisional Patent Application 60/428,282
?led Nov. 22, 2002. Additionally, all references and publi

Identi?cation of chemical compounds that bind to the

ligand-binding pocket of ultraspiracle, the Drosophila RXR
ortholog, has been stymied in part by di?iculty in demon
strating speci?c binding of a test compound to the puri?ed
receptor. Speci?cally, it has been di?icult to demonstrate
ligand binding because there has been no ef?cient assay for
detecting the conformational changes in a receptor upon

cations referred to herein are incorporated by reference for

their entirety, including Xu et al. (2002) Eur. J. Biochem.,
269:6026-6036.
BACKGROUND OF THE INVENTION

interaction betWeen a ligand and a USP and RXR. Indeed,

the current paradigm expressed in most published models
1. Field of the Invention

for USP function is that USP does not bind to any ligand in

This invention relates to the ?elds of drug discovery and
pest control. Speci?cally it provides biochemical tools and

exerting its regulatory functions. Lezzi et al., (1999)
Archives of Insect Biochemistry and Physiology, 41:99-106.

assays that enable the user to identify to chemical com

A demonstration that endogenous USP can become activated

pounds that are effective in activating or blocking particular

upon binding to an agonist Would have major implications

hormone-dependent regulatory pathWays in various organ

for the current paradigms of hormone action in invertebrates.
Jones et al., Proc Natl. Acad. Sci. USA., 94:13499-13503

isms.

2. Background

20

Nuclear hormone receptors are a primary transduction

The orthology betWeen invertebrate USP and vertebrate
RXR indicates that the USP ligand-binding pocket may be
arranged so as to be susceptible to binding and activation by

mechanism through Which extracellular hormonal signals
are transduced into genetic regulation of metabolic pathWays
and developmental programs. The past tWo decades have
seen the steady identi?cation of mammalian receptors of

a terpenoid-related ligand. In a previous report, it Was
25

Well-knoWn ligands such as steroids, thyroid hormone, all

endogenous ligands for initially orphaned receptors. Simi

gel shift assay. HoWever, these indirect experiments did not
address Whether methyl epoxyfarnesoate actually binds to
30

the ligand-binding pocket of the receptor, nor Whether
endogenous USP in the transfected cells actually binds to the

direct repeat elements, nor do they address Whether methyl
epoxyfarnesoate-activation of the reporter is dependent

hormonal signaling.
In parallel to the search for receptors that can be activated

by knoWn ligands, has been the search for ligands of orphan
receptors of the steroid nuclear receptor superfamily, Whose

observed that the application of methyl epoxyfarnesoate to
cells activated a transfected reporter construct containing
direct repeat elements to Which recombinant USP bound in

trans retinoic acid (RA) as Well as the identi?cation of

larly, steroid nuclear receptors in invertebrate models of
transcriptional regulation, such as the Drosophila melano
gasler ecdysteroid receptor (dEcR), Were isolated a decade
ago and used to develop important concepts in cellular

(1 997).

upon liganded USP, all of Which are crucial underpinnings
35

to the concept of the USP ligand-binding pocket as a viable

target for experimental or practical agonistic or antagonistic

ligands.

natural ligands are unknown. The biological relevance of

identi?cation of agonistic or antagonistic ligands for orphan
receptors is several fold. First, the ability of a chemical
structure to ?t into the ligand-binding pocket of an orphan

SUMMARY OF THE INVENTION
40

receptor and thereby transcriptionally activate the orphan
receptor, Would raise the possibility that the orphan receptor
ligand-binding pocket has a conformation enabling it to bind
With and be activated by a natural ligand of complementary
structure. Second, the identi?cation of ligands that activate
or antagonize an orphan receptor Would aid the discovery of

The invention relates to mutant nuclear hormone recep

tors that have either altered ?uorescence properties and/or

dominant negative activity.
45

One aspect of the invention relates to nucleic acids that
encode mutant nuclear hormone receptors, in Which particu

regulatory pathWays in Which the receptor participates.

lar amino acid residues are substituted With respect to Wild
type, so as to be able to detect ligand binding to the mutant

Finally, transcriptional agonists and antagonists of orphan

receptor by either a change in a physical property of the

receptors provide leads to pharmacologically or agri-chemi

cally signi?cant structures that, through the orphan receptor,

50

can selectively intercede in disease pathWays or insect

speci?c hormonal regulation.
In an effort to reduce the exposure of humans and other

non-target organisms to the toxic effects of pesticides, major
commercial efforts are being made to identify chemicals that

55

selectively disrupt the hormonal processes that are speci?c
to insects (e.g., humans do not have an exoskeleton that is

periodically shed, nor do humans go through metamorpho
sis, as insects do). TWo particular hormonal targets for these
commercial efforts are the insect hormones that drive molt

60

ing and metamorphosis: ecdysone and juvenile hormone.
Some commercial compounds mimicking these hormones
have already been developed, hoWever, the concern remains

that compounds interfering With insect hormonal signaling
may cross-react With mammalian hormone receptors. For
example, a metabolite of the juvenile hormone mimic
methoprene, binds the human RXR receptor, see Dhadialla

65

mutant receptor and/or an transcriptional induction of a
nuclear hormone receptor construct.
One embodiment of this aspect of the invention relates to
an isolated nucleic acid capable of hybridizing to SEQ ID

NO: 1 under stringent conditions and encoding a protein
having a tryptophan residue in a ?rst position corresponding
to position 477 of SEQ ID NO: 2 and a tryptophan residue
in a second position corresponding to position 479 of SEQ
ID NO: 2, Which upon binding an epoxy farnesoid-like
ligand results in transcriptional activation of a nuclear
hormone receptor reporter construct.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a

protein having a tryptophan residue in a ?rst position
corresponding to position 477 of SEQ ID NO: 2, Which upon
binding an epoxy farnesoid-like ligand results in transcrip
tional activation of a nuclear hormone receptor reporter
construct.

US 7,259,254 B2
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Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having a tryptophan residue in a ?rst position
corresponding to position 479 of SEQ ID NO: 2, Which upon
binding an epoxy famesoid-like ligand results in transcrip
tional activation of a nuclear hormone receptor reporter

third position corresponding to position 328 of SEQ ID NO:
2, Which upon binding an epoxy farnesoid-like ligand results
in transcriptional activation of a nuclear hormone receptor
reporter construct.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a

protein having an tryptophan residue in a ?rst position
corresponding to position 498 of SEQ ID NO: 2, a tryp
tophan residue in a second position corresponding to posi
tion 499 of SEQ ID NO: 2, and phenylalanine residue in a
third position corresponding to position 318 of SEQ ID NO:
2, and phenylalanine residue in a fourth position correspond
ing to position 328 of SEQ ID NO: 2, Which upon binding
an epoxy farnesoid-like ligand results in transcriptional

construct.

Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having a tryptophan residue in a ?rst position
corresponding to position 302 of SEQ ID NO: 2, Which upon
binding an epoxy famesoid-like ligand results in transcrip
tional activation of a nuclear hormone receptor reporter

activation of a nuclear hormone receptor reporter construct.
Another aspect of the invention relates to a nucleic acids
that encode dominant negative mutant nuclear hormone

construct.

Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having a tryptophan residue in a ?rst position
corresponding to position 315 of SEQ ID NO: 2, Which upon
binding an epoxy famesoid-like ligand results in transcrip
tional activation of a nuclear hormone receptor reporter

receptors.
20

One embodiment of this aspect of the invention relates to
an isolated nucleic acid capable of hybridizing to SEQ ID
NO: 1 under stringent conditions and encoding a protein
having an phenylalanine residue in a ?rst position corre
sponding to position 318 of SEQ ID NO: 2, Which is a

25

dominant negative nuclear hormone receptor.

construct.

Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a

protein having a phenylalanine residue in a ?rst position
corresponding to position 318 of SEQ ID NO: 2, Which upon
binding an epoxy famesoid-like ligand results in transcrip

30

tional activation of a nuclear hormone receptor reporter
construct.

Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a

35

protein having a phenylalanine residue in a ?rst position
corresponding to position 328 of SEQ ID NO: 2, Which upon
binding an epoxy famesoid-like ligand results in transcrip
tional activation of a nuclear hormone receptor reporter
construct.

Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having a phenylalanine residue in a ?rst position
corresponding to position 318 of SEQ ID NO: 2, and a
phenylalanine residue in a second position corresponding to
position 328 of SEQ ID NO: 2, Which upon binding an

40

dominant negative nuclear hormone receptor.
45

epoxy famesoid-like ligand results in transcriptional activa
tion of a nuclear hormone receptor reporter construct.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to

SEQ ID NO: 1 under stringent conditions and encoding a
protein having an tryptophan residue in a ?rst position
corresponding to position 498 of SEQ ID NO: 2, a tryp
tophan residue in a second position corresponding to posi
tion 499 of SEQ ID NO: 2, and phenylalanine residue in a
third position corresponding to position 318 of SEQ ID NO:
2, Which upon binding an epoxy farnesoid-like ligand results
in transcriptional activation of a nuclear hormone receptor
reporter construct.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a

protein having an tryptophan residue in a ?rst position
corresponding to position 498 of SEQ ID NO: 2, a tryp
tophan residue in a second position corresponding to posi
tion 499 of SEQ ID NO: 2, and phenylalanine residue in a

One embodiment of this aspect of the invention relates to
an isolated nucleic acid capable of hybridizing to SEQ ID
NO: 1 under stringent conditions and encoding a protein
having a phenylalanine residue in a ?rst position corre
sponding to position 318 of SEQ ID NO: 2, and a pheny
lalanine residue in a second position corresponding to posi
tion 328 of SEQ ID NO: 2, Which is a dominant negative
nuclear hormone receptor.
One embodiment of this aspect of the invention relates to
an isolated nucleic acid capable of hybridizing to SEQ ID
NO: 1 under stringent conditions and encoding a protein
having an tryptophan residue in a ?rst position correspond
ing to position 498 of SEQ ID NO: 2, a tryptophan residue
in a second position corresponding to position 499 of SEQ
ID NO: 2, and phenylalanine residue in a third position
corresponding to position 318 of SEQ ID NO: 2, Which is a

50

55

60

65

One embodiment of this aspect of the invention relates to
an isolated nucleic acid capable of hybridizing to SEQ ID
NO: 1 under stringent conditions and encoding a protein
having an tryptophan residue in a ?rst position correspond
ing to position 498 of SEQ ID NO: 2, a tryptophan residue
in a second position corresponding to position 499 of SEQ
ID NO: 2, and phenylalanine residue in a third position
corresponding to position 318 of SEQ ID NO: 2, and
phenylalanine residue in a fourth position corresponding to
position 328 of SEQ ID NO: 2, Which is a dominant negative
nuclear hormone receptor.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having an alanine residue in a ?rst position corre
sponding to position 472 of SEQ ID NO: 2 and leucine
residue in a second position corresponding to position 475 of
SEQ ID NO: 2, Which is a dominant negative nuclear
hormone receptor.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having an arginine residue in a ?rst position corre
sponding to position 302 of SEQ ID NO: 2, Which is a

dominant negative nuclear hormone receptor.

US 7,259,254 B2
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Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having an arginine residue in a ?rst position corre
sponding to position 293 of SEQ ID NO: 2, Which is a

embodiment of the invention is shoWn and described, simply
by Way of illustration of the best mode contemplated of
carrying out the invention. As Will be realized, the invention
is capable of other and different embodiments, and its
several details are capable of modi?cations in various obvi
ous respects, all Without departing from the invention. The
present invention may be practiced Without some or all of
these speci?c details. In other instances, Well knoWn process
operations have not been described in detail, in order not to

dominant negative nuclear hormone receptor.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having an alanine residue in a ?rst position corre
sponding to position 288 of SEQ ID NO: 2, Which is a

unnecessarily obscure the present invention. Accordingly,
the draWings and description are to be regarded as illustra

dominant negative nuclear hormone receptor.

tive in nature, and not as restrictive.

Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having an alanine residue in a ?rst position corre
sponding to position 366 of SEQ ID NO: 2, Which is a

BRIEF DESCRIPTION OF THE DRAWINGS

dominant negative nuclear hormone receptor.
Another embodiment of this aspect of the invention
relates to an isolated nucleic acid capable of hybridizing to
SEQ ID NO: 1 under stringent conditions and encoding a
protein having an alanine residue in a ?rst position corre
sponding to position 366 of SEQ ID NO: 2 and an alanine
residue in a second position corresponding to position 288 of
SEQ ID NO: 2 Which is a dominant negative nuclear

20

half site is dashed underlined. Mutated residues are shoWn
in loWer case letters. (B) On the left are the designs of the
25

hormone receptor.
Another aspect of the invention relates to a method

identifying ligands of nuclear hormone receptors compris

vector construct encoding the luciferase reporter enzyme, of
the vector construct containing the Core promoter reporter,
and of the three vector constructs in Which the Core pro
moter is preceded by four tandem copies either a DRl-, a
DR4- or a DRl2-based enhancer, With the orientation of
each motif shoWn by the small arroWs. On the right are the

ing: contacting a mutant nuclear hormone receptor protein
With a candidate ligand; and determining Whether there is a
change in a physical property of the protein or a change in

FIG. 1. Activation of transfected Core promoter reporter
through DRl2 nuclear hormone response element. (A) The
sequences of single copies of DRl (SEQ ID NO:l3), DR4
(SEQ ID NO:14), DR12 (SEQ ID NO:15) and mutant DR12
(SEQ ID NO:23) enhancer elements, i.e. motifs, used in the
nuclear hormone receptor response reporter constructs. Each

30

activations of the indicated nuclear hormone receptor
response reporter construct in response to treatment of

the transcriptional activity of the protein.

transfected cells With 75 um methyl epoxyfamesoate.

In one embodiment of this aspect of the invention, the
protein is a mutant USP receptor. In another embodiment,
the protein is a mutant RXR receptor. In yet a further the
embodiment, the ligand causes a change in the ?uorescence

FIG. 2. Functional analysis of the DRl2 motif. (A) Gel
mobility shift assay, using Sf9 nuclear extracts, of the same
35

single DRl2 motif that Was used as an enhancer in the cell

transfection assay in (B). The shifted probe band Was

properties and/or transcriptional activity the mutant USP

competitively displaced by l00>< of the unlabelled DRl2

receptor mutant nuclear hormone but not in the mutant RXR

motif (self), but Was not competed With either by the same

receptor.
Another aspect of the invention relates to a nuclear

mutant DRl2 motif as failed to act as an enhancer in cell
40

NO: 8) and a reverse DR sequence is 5'-TGACCT(N),C
TGACCT-3' (SEQ ID NO: 9); Wherein the element com

indicated promoter reporter constructs in response to treat

ment of transfected cells With 75 um methyl epoxyfame
soate. (C) Intracellular USP binds to DRl2 hormone
45

prises at least one DR oriented in either a forWard or reverse

orientation; Wherein Y equals 1 to 8 forWard and/or reverse
direct repeats; and X equals 1 to about 12.
Another aspect of the invention relates to nuclear hor
mone receptor reporter construct comprising a nuclear hor

50

the major binding complex (small arroW) is displaced by the
ABll monoclonal antibody, just as We have previously
shoWn is the effect of this antibody on recombinant dUSP
binding to a DRl2 probe Jones et al. (2001) Insect Biochem.
Mol. Biol. 32, 33-49. The lack of similar effect by mono

55

clonal antibody against the negative control nerve transcrip

60

tion factor (Elav) shoWs the speci?city of the ABll result.
FIG. 3. Comparision of dUSP and hRXR ligand binding
domains. (A) Selected contacts made betWeen 9-cis RA and
residues in the hRXRO. ligand-binding pocket as determined
from cocrystals (4.2 A or less, from Egea et al. (2000)

a forWard DR sequence is 5'-AGGTCA(N)xAGGTCA-3'
(SEQ ID NO: 8) and a reverse DR sequence is 5'-TGACCT

(N)xTGACCT-3' (SEQ ID NO: 9); Wherein the element
comprises at least one DR oriented in either a forWard or

response element. Gel mobility shift assay using Sf9 nuclear
extracts (NE) and a 32P-labelled probe that is the four
tandem DRl2 motifs (‘4DRl2’) shoWn in FIG. 1, performed
as described in Jones et al. (2001) Insect Biochem. Mol.
Biol. 32, 33-49. The USP in the Sf9 nuclear extract that is

mone receptor response element, a promoter and a reporter
nucleic acid sequence operably linked to one another;

Wherein the hormone receptor response element denoted by
the formula YDRX comprises a direct repeat (DR) compris
ing tWo half sites separated by X nucleic acid bases; Wherein

transfection assay in B (mutDRl2) or by the negative

control polylinker sequence (nonself). (B) Activations of the

hormone receptor response element denoted by the formula
YDRX comprising a direct repeat (DR) comprising tWo half
sites separated by X nucleic acid bases; Wherein a forWard
DR sequence is 5'-AGGTCA(N)xAGGTCA-3' (SEQ ID

reverse orientation; Wherein Y equals 1 to 8 forWard and/or
reverse direct repeats; and X equals 1 to about 12; and

conformation of epoxyfamesoic acid, exhibiting similarities

Wherein the promoter is selected from the group consisting

betWeen its structure and that of the terpenoid backbone and

of JHE, BJHSP l, Aryl, BJHSP2, and AJHSPl.
Additional advantages of the present invention Will
become readily apparent to those skilled in this art from the

folloWing detailed description, Wherein only the preferred

EMBO J. 19, 2592-2601). On the left is also shoWn a
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carboxyl group of 9-cis retinoic acid. (B and C) RASMOL
generated ribbon diagrams for the ligand-binding domains
of the hRXRO. and dUSP, respectively. (B) This shoWs in the
hRXRO. ligand-binding pocket the structure of the ligand
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9-cis retinoic acid. (C) This shows methyl epoxyfarnesoic
acid lain manually in the dUSP ligand-binding pocket With
the carboxy and distal (epoxy) ends, respectively, situated in

mutation to the ligand-binding pocket in C475A/H475L did
not generally disrupt the structure of the receptor. (B) The
homodimer-enriched fraction of each receptor preparation
Was then analyZed for binding to 75 um methyl epoxyfar

similar regions of the pocket as the carboxyl end and distal
end of 9-cis RA in hRXRot. (D) An overlay of the dUSP and

nesoate, using an intrinsic ?uorescence assay method that

tracks ligand binding (by suppression in receptor ?uores

hRXR ribbon diagrams of B and C, With emphasis (White
arroWs) on the similar placement of Gln275, Trp305,

cence) Jones et al., (2000) Insect Biochem. Mol. Biol. 30,
671-679; Jones et al. (2001), Insect Biochem. Mol. Biol. 32,
33-49. The Wild-type dUSP exhibited binding to methyl
epoxyfarnesoate in this assay. HoWever, the double mutant

Leu326, Cys432 and His435 in hRXR as compared to

Gln288, Trp318, Leu367, Cys472 and His475 in dUSP.
FIG. 4. Dominant negative activity of USP ligand-binding
pocket mutants. (A) Histogram (shaded boxes) shoWs the

dUSP exhibited no binding activity. ArroWs shoW time of
addition of methyl epoxyfarnesoate or EtOH carrier.
FIG. 6. Fluorescence response of Wild-type and P498W/
P499W mutant USP to farnesoid ligands. (A) The location of
the mutational placement of the tWo tryptophan residues at

dominant negative effect of transfected dUSP mutant and the

double mutant (C472A/H475L) on methyl epoxyfarnesoate
activation of4DR12Core reporter promoters, Whereas trans
fected Wild-type dUSP shoWs no such suppression of methyl

epoxyfarnesoate activation, in comparison With transfection
of Core reporter vector (reporter and expression plasmids

the end of ot-helix 12. USP also possesses tWo natural

transfected at 1:1 ratio). Transfection of neither the Wild

pocket; W328, not shoWn, extending out of pocket). (B)
Methyl epoxyfarnesoate binding to Wild-type USP results in
suppression of receptor ?uorescence, While famesol and

tryptophan residues on helix 5 (W318, shoWn extending into

type USP nor either mutant had any effect on the minimal

basal activation of the Core promoter in the absence of the
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ethanol carrier do not have that effect. (C) Methyl epoxy

DR12 motif (clear boxes). Immunoblot of transfected cel
lular extracts With anti-(ot-actin) and anti-dUSP (AB11)

farnesoate binding to P498W/P499W mutant results in a

mAbs veri?ed that the overexpression of mutant and Wild
type dUSP did not affect the level of expression of endog

very different pattern of ?uorescence response than Wild
type USP in B, evidencing that ot-helix 12 moves in its

enous USP, and that the transfected mutant and transfected
Wild-type dUSP Were expressed at similar levels to each

25

other. The molecular Weights of the transfected and endog
enous USPs detected by immunoblotting Were about equal
to 50 and 52 kDa, respectively, as estimated by molecular

siZe standards run in parallel lanes (not shoWn). (B) Pro
gressive increase in ratio of transfected dominant negative
plasmid DNA relative to 4DRl2Core reporter plasmid DNA
yielded an increasing dominant negative suppression of

relative location upon USP binding of methyl epoxyfame
soate. The Wild-type USP and P498W/P499W similarly
bound in part as monomer and in part as dimer to a DR12

probe in gel shift assay, evidencing that the P498W/P499W
mutations did not affect receptor structure globally (not
30

shoWn).
DETAILED DESCRIPTION OF THE
INVENTION

methyl epoxyfarnesoate activation of reporter plasmid.
Immunoblot veri?es that the progressively higher overex
pression of the mutant dUSP (C472A/H475L) did not affect
the level of expression of endogenous USP. Inset above
shoWs calculation of transcriptional activation ratio of

35

reporter promoter activity in methyl epoxyfarnesoate-treated
cells relative to EtOH treated cells, as a function of the ratio

40

of the amount of transfected mutant dUSP plasmid relative

to amount of transfected reporter plasmid. (C) Transfection
of plasmid expressing Wild-type USP rescues the dominant

Before describing the invention in greater detail the
folloWing de?nitions are set forth to illustrate and de?ne the
meaning and scope of the terms used to describe the inven
tion herein:
As used herein, “Wild type” refers to the nucleic acid or
amino acid sequence of a particular protein as it most
commonly occurs in nature as a normal functional protein.
Nonetheless, it is elementary to one of skill in the art that

such functional proteins have allelic variations. An allele is

negative-suppression of methyl epoxyfamesoate-activation
of the reporter promoter. Open circle, methyl epoxyfarne

one of several alternate forms of a gene that can have the
45 same locus on homologous chromosomes and are respon
sible for alternative traits. Some alleles are dominant over
soate activation of 4DRl2Core in the absence of USP

expressing plasmid. Hashed circle, methyl epoxyfarnesoate
activation is suppressed by transfection With the C472A/
H475L dominant negative mutant. Filled circles, methyl

epoxyfarnesoate activation is progressively restored by
increasing doses of plasmid expressing Wild-type dUSP. In

50

A-C, hormone-treated cells received 75 pm of methyl

epoxyfarnesoate.
FIG. 5. Bacterially overexpressed double mutant dUSP

(C472A/H475L) and Wild-type dUSP analyZed for binding
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treatment of signi?cant diseases such as cancer, coronary

heart disease through the regulation of serum cholesterol and
diabetes. The nuclear receptor family contains a large group

to DNA or to ligand. (A) The Wild-type dUSP and the
C472AH475L mutant both similarly bound in part as a

homodimer (upper band) and in part as a monomer (loWer
band) to a 4DRl2 motif probe (identi?cation of monomer

and homodimer bands Was made by comparative analysis of
binding by other dimer-enriched vs. monomer-enriched
fractions obtained from Superdex 200 chromatography, not
shoWn). Control competitions With self and nonself unla
belled excess probes con?rmed the speci?city of binding.
The similar formation of the homodimer form by the Wild
type USP and mutant USP, along With the similar binding to
DNA of the Wild-type USP and mutant USP, con?rm that the

others. Such normal variation are encompassed Within this
term. Preferably, the Wild type USP nucleic acid sequence is
provided in SEQ ID NO: 1 and the Wild type amino acid
sequence is provided in SEQ ID NO: 2.
“Ligands” as de?ned herein are those compounds likely
agonists or antagonists in the activation RXR and/or USP.
Nuclear receptors are a family of proteins involved in key
metabolic processes With great potential as targets for the

60

of transcription factors, With 49 members presently identi
?ed in the human genome. Many members of this family
remain incompletely understood, both in terms of physi
ological role and activating ligands, but there is a high
probability that these “orphan receptors” are good targets for
drug development. As such, ligands may act as drug leads in
the treatment of diseases Where nuclear hormone receptors
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are thought to play a role such as in the. For example, a
nuclear receptor LXR forms RXR/LXR to induce ABC1
reverse transporter of cholesterol to pump out cellular cho
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lesterol, resulting in lowering dietary cholesterol. Still

substitutions With respect to Wild type nuclear hormone
receptors. In one embodiment, these mutations comprise
amino acid substitutions that serve to give make changes in
protein con?rmation due to interaction With a putative

another nuclear receptor FXR forms RXR/FXR to induce

cytochrome P450 hydroxylase CYP7A1 that metaboliZes
cholesterol to bile acid to again loWer cholesterol level.

Small molecular ligands that speci?cally bind to each
nuclear receptor are novel drugs against hyperlipidemia.
Ligands identi?ed using the compositions and methods

ligand, more easily detectable by providing the protein With
altered ?uorescent properties. More preferably, amino acid
substitutions are made in the ligand biding domain of the
nuclear hormone receptors. Even more preferably, amino
acids substitutions are made in the ligand binding domain of

disclosed herein may be useful in the activation or inhibition

of signal transduction mediated by USP, RXR or other
nuclear hormone receptors. These ligands are mostly ana
logs of RXR compounds that bind to and activate RXR.

USP or RXR.

Whereas, ligand binding does not su?iciently modulate

Alternatively, the compositions and methods disclosed
herein provide the ability to identify ligands useful in pest

the ?uorescence of Wild type receptors to facilitate ligand
binding detection, some of the mutant receptors disclosed
herein have markedly different ?uorescent pro?les upon
binding a ligand. The change in ?uorescence of a mutant
receptor upon ligand binding can be detected by such
exemplary techniques as anisotropy, Fluorescence Reso

control that antagoniZe USP signaling While not cross

reacting With mammalian RXR signal transduction. Prefer

ably, such compounds are terpenoid-related compounds.
More preferably, ligands are structurally related to juvenile
hormone III, retinoic acid, or epoxy famesoid-like com

nance Energy Transfer (FRET), or circular dichroism. Pref

pounds.
“Activation” refers to the homo- or heterodimeriZation of

nuclear hormone receptors to With their natural partners
upon ligand binding to form a complex that is capable of
binding a nuclear hormone receptor response element and
inducing transcription of a gene operably linked thereto.
“Transcriptional activity” of a protein or nuclear hormone

20

order to detect binding to the ligand binding pocket of the
test mutant receptor by chemical compounds that do not
25

receptor as used herein refers to the ability of a nuclear
hormone receptor to homo- or heterodimeriZe, bind a

nuclear hormone receptor response element and induce the
30

family of proteins. Such receptors are also transcription
factors, binding hormone ligands and acting together With
others in the superfamily to activate transcripts of hormone
responsive genes. RXR plays a uniquely important role in
di?ferentiation, development, and homeostasis through its

mutant protein forms a dimer With an integral part of a Wild
40

folloWing ligand or independent of ligand binding. Prefer
45

complex of a mutant and its endogenous Wild type partner
Will be incapable of initiating transcription at a hormone

receptor response reporter gene. Assays for determining
dominant negative activity may be found in Examples 6 and
7 as Well as FIG. 4.
50

meaning it can dimeriZe With multiple partners. It is homolo
gous to the vertebrate retinoid-X receptor, Which demon
strates the ancient lineage of the nuclear receptor superfam
55

In yet another embodiment, mutant nuclear hormone
receptors have both altered ?uorescent properties upon
ligand binding as Well as dominant negative activity. For
example, USP W318F is a Weak dominant negative that by
the elimination of the ?uorescence emitting tryptophan from
W318 also enables more sensitive tracking of the tracking of
changes in ?uorescence emitted by W328. W328F is not a

hormone in insects, USP activates genes involved in molt
ing. Another target is the larval serum protein-2 gene Whose

dominant negative. HoWever, elimination of the ?uores

product accumulates in the fat body tissue. This implicates
USP in the functioning of the fat body in larval ?ies
(AntonieWski, 1994). The fat body serves as an energy store

acts With a Whole range of native compatible gene products.
Preferably, the mutant homodimeriZes or heterodimeriZes
With an endogenous Wild type partner to form a complex
ably, as opposed to a complex of Wild type monomers, a

some pathological conditions as neoplastic formation and it
is a potential target for cancer therapy.

ily. Partnering the Ecdysone receptor for the molting

negative proteins exploit protein-protein interactions, i.e.,

type endogenous protein molecule. The mutant protein inter

di?ferentiation, bone development, hematopoesis and pattern
formation during embryogenesis. RXR is also implicated in
As used herein, “USP” refers the Drosophila melano
gasler protein Ultraspiracle. USP is a promiscuous factor,

a dimer pair, i.e., formation of “homodimer”.
In another embodiment, mutant nuclear hormone recep
tors disclosed herein comprise amino acid substitutions that
the interactions betWeen a mutated protein produced by a
transgene and the related native protein inside the cell. The

family proteins, i.e. DNA-binding domain and ligand bind
ing domain (LBD). The endogenous ligand for RXR is 9-cis
retinoic acid. RXR plays an important role in many funda
mental biological process such as reproduction, cellular

pocket Whose e?fects on the receptor are to either promoter
or inhibit the binding of tWo identical mutant molecules into

render the mutant to act as a “dominant negative.” Dominant
35

ability to serve as a heterodimeric partner to many other

nuclear receptors. RXR is a ligand-dependent transcription
factor. RXR is able to in?uence the activity of its partner
receptors through the action of the ligand 9-cis retinoic acid.
RXR contains tWo signature domains of nuclear receptor

themselves signi?cantly absorb the ?uorescent light emitted

by the receptor. Alternatively, changes in the anisotropy
(rotational volume) of the mutant receptor are monitored in
order to detect binding of chemical compounds to the ligand

transcription of any nucleic acid operably linked thereto.
As used herein “RXR” refers to the retinoid X receptor
(RXR) Which is a member of the nuclear hormone receptor

erably, changes in ?uorescence emission (either the magni
tude of emission or the blue-red shift in emission) of
tryptophan residues in the mutant receptor are monitored, in

cence emitting tryptophan from W328 enables more sensi

tive tracking of the in ?uorescence emitted by W318.
60

P498W/P499W is not a dominant negative, but is used to

for high levels of activity and for reproduction. In contrast

detect the movement of alpha helix 12. HoWever, the

to RXR, prior to this disclosure, USP Was not not knoWn to
have knoWn high-a?inity ligand and Was thought to be a

P498W/P499W is not the most e?icient ?uorescent detector
of movement of alpha helix 12 because of the additional

silent component in the heterodimeric complex With partner
receptors such as the ecdysone receptor.
As used herein “mutant nuclear hormone receptors” as

used herein refers to protein having speci?c amino acid

?uorescence being contributed by the Wild type residues
65

W318 and W328. So, When either W318, W328 or both are
mutated aWay as W318F and/or W328F, removal of their

contributing “background” ?uorescence enables the ?uores
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cent signaling from P498W/P499W to be more sensitive,

van der Waals volume of the USP ligand-binding pocket

indicating movement of alpha helix 12.

(:1300 A3), compared to the volume of JH III (259 A3
Bogan, et al., (1998) Nat. Struct. Biol. 5, 679-681). HoW
ever, the volume of the PPARY ligand-binding pocket (simi

A list of some of the mutants envisioned by the invention
is summarized in Table 1 beloW:

lar to that of USP, :1300 A3 Nolte et al. (1998) Nature 395,
137-143) is also much larger than that of its natural ligand
15-deoxy-Al2’l4-prostaglandin J2 (Which has a volume simi
lar to that of JH III, at 301 A3 Bogan, et al., (1998) Nat.

Altered Fluorescence

USP Mutant

With Respect

Dominant

to Wild Type

Negative Activity

Struct. Biol. 5, 679-681), yet this prostaglandin ligand is
10

+
l

able to bind and transcriptionally activate the PPARY;
KlieWer et al (1995) Cell 83, 813-819. In addition, the
volume of [3-estradiol (Which at 245-251 A3 is smaller than

methyl epoxyfarnesoate; Bogan, et al., (1998) Nat. Struct.
Biol. 5, 679-681), is approximately half the volume of the

ligand-binding pocket of the estrogen receptor (450-500 A3 ;
Weak Activity

BrZoZoWski, et al (1997) Nature 389, 753-758., Shiau, et al

(1998) Cell 95, 927-937), Yet, [3-estradiol is nonetheless able

Weak Activity
Weak Activity
Weak Activity

20

to bind to and activate the estrogen receptor. Thus, PPARY
and the estrogen receptor demonstrate that endogenous
compounds much smaller than the total ligand-binding
pocket volume of a nuclear hormone receptor can and do

+

serve as natural activating ligands. The recently crystallized
PXR, Which binds With, and is activated by, a variety of
small and large ligands, also possesses a large 1300 A3
25

ligand-binding pocket [Watkins et al., (2001) Science 292,

30

amino acids that the authors postulated enables What Would
otherWise be a smaller PXR ligand-binding pocket to
enlarge to accommodate a large ligand. Important in these
considerations is Whether there is a subregion in the ligand

2329-2333, and possesses an unusual additional stretch of

Amino acid residue positions “corresponding” to one
another as used herein, refers to the fact that there are

conserved amino acid residues among orthologous proteins

binding pocket in Which the local conformation corresponds

or among structurally similar mutant receptors that are

Well to the conformation of a particular small ligand.

encoded by substantially identical nucleic acids. Corre
sponding amino acids may be the same amino acids or they
may be differing amino acids sharing one or more charac

teristics With respect to charge, polarity, acidity, hydrophi

35

the ligand-binding pocket of hRXR and USP are much more

licity, hydrophobicity, or siZe. Preferably, the USP mutations

similar in volume and shape Clayton et al., (2000) Proc.
Natl. Acad. Sci. USA 98, 1549-1554. The proximal subre
gion of each of the tWo receptors also has a similar place

disclosed in Table 1 are made in corresponding amino acids
of RXR and other nuclear hormone receptors.

For exemplary purposes, in human RXR, Cys432 and

40

His435 on ot-helix 11 make contact With the distal end of the

van der Waals volumes of 291 and 258 A3, respectively
Bogan, et al., (1998) Nat. Struct. Biol. 5, 679-681. These
45

agonists, merely on the basis of comparison of the volume
of methyl epoxyfarnesoate vs. the reported total volume of

Billas et al. (2000) J. Biol. Chem. 276, 7465-7474., Clayton
et al. (2000) Proc. Natl. Acad. Sci. USA 98, 1549-1554).
conserved in identity and similar location in the ligand
binding pocket of USP, such as Gln288, Trp318 and Leu3 67
in USP corresponding to Gln275, Try305 and Leu326 of
RXR, respectively (FIG. 3B-D). If an epoxy famesoid-like
ligand Were to reside in the USP ligand-binding pocket along

considerations suggest that methyl epoxyfamesoate-like
metabolites cannot be dismissed a priori as potential USP

ligand-binding pocket of USP crystal structures (FIG. 3C,
Other residues that contact 9-cis RA in hRXR are also

ment of conserved amino acids that in hRXR interact With

the terpenoid backbone of 9-cis RA (FIGS. 4A-D). In
addition, 9-cis RA and methyl epoxyfarnesoate have similar

9-cis RA ligand at tWo methyl branches (C 16, C 17) and
also at the terpene backbone (FIGS. 3A,B). The correspond
ing tWo residues on ot-helix 11 of Drosophila USP (Cys472
and His475) are highly conserved in other USPs Jones et al.,
Insect Biochem. Mol. Biol. 30, 671-679; and point into the

Although the overall volume of the ligand-binding pocket
observed in the cocrystals of USP (:1300 A3) is much larger
than that of hRXRO. (:500 A3), the proximal subregion of

50

the USP ligand-binding pocket.
Given this disclosure exemplary corresponding amino
acid positions in conjunction With standard protein align
ment or 3-D modeling softWare common in the art, one of

skill in the art Would readily be able to determine the
location of other corresponding amino acids residues inside
55

a similar trace as does 9-cis RA in RXR, then the terpene
backbone and the methyl branches C 12 and C 15 at the

and outside the ligand binding pocket of USP, RXR and
other nuclear hormone receptors.
The term “nuclear hormone receptor response reporter

distal end of the epoxy famesoid ligand might be similarly

construct” as used herein refers to a segment of DNA that

placed to interact With His475 and Cys472 in USP, as does
9-cis RA interact With Cys432 and His435 in RXR (FIG.

comprises an operably linked nuclear hormone receptor
response element, core promoter and reporter gene nucleic

60

3B-D).

acid. These constructs are used to test Whether ligand
binding of a nuclear hormone receptor causes the receptor to

USPs, Which compared to RXR are unusual for their
stretch of additional amino acids inserted after ot-helix 5,

have recently been cocrystaliZed With fortuitous phospho
lipid pseudoligands Billas et al. (2000) J. Biol. Chem. 276,
7465-7474., Clayton et al. (2000) Proc. Natl. Acad. Sci. USA
98, 1549-1554. These cocrystals had a relatively large total
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induce transcription of its target gene as assayed by expres
sion of the reporter gene nucleic acid or by the activity of the
reporter gene nucleic acid translational product.
One embodiment of the nuclear hormone receptor
response reporter construct has a an Aryl core (SEQ ID NO:

US 7,259,254 B2
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6) operably linked to a tWo copies of an EcRERF (SEQ ID
NO: 7) nuclear hormone receptor response element. Prefer
ably, other embodiments have a hormone receptor response
element denoted by the formula YDRXZ having a direct
repeat (DR) operably linked to a core promoter represented

An another embodiment, the nuclear hormone receptor
response element comprises the hormone response element
EcRE having the sequence 5; GAGGTCAATGACCTC-3'

(SEQ ID NO: 7).
The term “core promoter region” refers to a DNA
sequence that acts as a site of initiation for the formation of
a transcriptional complex that Will transcribe one or more

by SEQ ID NOs: 3, 4, 5, or 6.
The term “operably linked” refers to the linkage of a DNA

nucleic acid sequences. It is located upstream With respect to

segment to another DNA segment in such a Way as to alloW
the segments to function in their intended manners. A DNA

the direction of transcription of the transcription initiation
site of the gene, and is structurally identi?ed by the presence
of a binding site for DNA-dependent RNA polymerase and
transcription initiation sites. Mo st preferably, the promoter is

sequence encoding a gene product is operably linked to a

regulatory sequence When it is ligated to the regulatory
sequence, such as, for example, promoters, enhancers and/or

doWn stream of and operably linked to the nuclear hormone
response element. More preferably, the promoter is the

silencers, in a manner Which alloWs modulation of transcrip
tion of the DNA sequence, directly or indirectly. For
example, a DNA sequence is operably linked to a promoter
When it is ligated to the promoter doWnstream With respect
to the transcription initiation site of the promoter, in the
correct reading frame With respect to the transcription ini

BJHSPI core promoter, the JHE core promoter (SEQ ID

NO: 22), BJHSP2Core (SEQ ID NO: 5), AJHSPlCore (SEQ
ID NO: 3), BJHSPl (SEQ ID NO: 4) or the ArylCore (SEQ
ID NO: 6). These core promoter sequences are described in

tiation site and alloWs transcription elongation to proceed
through the DNA sequence. An enhancer, such as the

Jones et al., (1995) Gene, 173: 209-214.
20

The term “induction” refers to an increase in nucleic acid

envisaged nuclear hormone receptor response element, is

sequence transcription or expression brought about by

operably linked to a promoter and a DNA sequence coding
for a gene product When they are ligated to the DNA

nuclear hormone receptor response element binding of a
ligand activated/homo- or heterodimeriZed nuclear hormone
receptor relative to some basal level of transcription. Pref
erably, hetero- or homodimeriZed ligand bound nuclear
hormone receptor binds to a nuclear hormone receptor
response element and induces transcription of a reporter
gene as measured by construct activity.
The term “construct activity” refers to the extent of
expression of a nucleotide sequence that is operably linked
to the nuclear hormone receptor response reporter construct

sequence in such a manner as to increase or decrease,

respectively, the transcription of the DNA sequence.

25

Enhancers and silencers may be located upstream, doWn
stream or embedded Within the coding regions of the DNA
sequence. Linkage of DNA sequences to regulatory

sequences is typically accomplished by ligation at suitable
restriction sites or via adapters or linkers inserted in the
sequence using restriction endonucleases knoWn to one of
skill in the art.
The term “nuclear hormone receptor response element”
refers to a segment of DNA that is a target of ligand
activated/homo- or heterodimeriZed nuclear hormone recep

30

Whose activity is being measured. Construct activity may be
measured directly by determining the amount of RNA

transcript produced, for example by Northern blot analysis
35

or indirectly by determining the amount of product coded for

tor Which acts as an enhancer that When bound causes

by the linked nucleic acid sequence, such as a reporter

initiation of the formation of a transcriptional complex to
being at the core promoter to Which the element is operably

nucleic acid sequence linked to the promoter. Alternatively,

linked. In one embodiment, a hormone receptor response

element is denoted by the formula YDRXZ comprising a

40

construct activity is measured as a function of the activity of
a protein encoded by a reporter nucleic acid sequence
operably linked to the receptor response element and core

direct repeat (DR) having tWo half sites separated by X

promoter.

nucleic acid bases; Wherein a forWard DR sequence is
5'-AGGTCANxAGGTCA-3' (SEQ ID NO: 8) and a reverse

A “reporter nucleic acid sequence” is a DNA molecule
that expresses a detectable gene product, Which may be RNA

DR sequence is 5'-TGACCTNxTGACCT-3' (SEQ ID NO:
9); Wherein the element comprises at least one DR oriented

or protein. The detection may be accomplished by any
45

detection of mRNA expression may be accomplished by
using Northern blot analysis and detection of protein may be
accomplished by staining With antibodies speci?c to the
protein, e.g. Western blot analysis. Preferred reporter nucleic

in either a forWard or reverse orientation as indicated by Z

(“f”:forWard, “r”:reverse); WhereinY equals 1 to 8 forWard
and/ or reverse direct repeats; and X equals 1 to about 12. For

example, the DRlf refers to “direct repeat l-forWard.” This
means that there is a single forWard oriented DR sequence
With tWo half-sites, With a single nucleotide space betWeen
the tWo half-sites. As such, DRlf has the sequence AGGT
CANAGGTCA (SEQ ID NO: 10), Wherein N is any base.
The invention also envisages hormone response elements in

50

various orientations. For example, 2DRllf might represent

55

AGGTCANAGGTCAAGGTCANAGGTCA (SEQ ID NO:
11; tWo adjacent DRs in the same orientation) and 2DRlfr
AGGTCANAGGTCATGACCTNTGACCT (SEQ ID NO:
12; tWo adjacent DRs in the opposite orientation as the ?rst
example.) One of ordinary skill in the art could readily

acid sequences are those that are readily detectable. A

reporter nucleic acid sequence may be operably linked in a
DNA construct With a nuclear hormone receptor response

element such that detection of the reporter nucleic acid
sequence product provides a measure of the construct activ

ity of the regulatory sequence. Examples of reporter nucleic
acid sequences include, but are not limited to, those coding

for alkaline phosphatase, chloramphenicol acetyl transferase
(CAT), luciferase, beta-galactosidase and alkaline phos

phatase.
60

appreciate the potentially large number of variations and
combinations envisaged. Preferably, the nuclear hormone
receptor response element is a DRl, DR2, DR4, or DRl2

response element With the proviso that envisaged receptor
response element does not include a speci?c 4DRl2iffr
element With a reverse oriented DRl2 preceded by three
forWard oriented DRl2s.

method knoWn to one of skill in the art. For example,
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Construction of expression vectors containing the novel
nuclear hormone receptor response reporter constructs, can
be accomplished by methods knoWn to one of skill in the art.
Typically nuclear hormone receptor response reporter con
struct Will be cloned into an expression vector via suitable
restriction endonuclease sites. The expression vector may be
a plasmid, virus or a cosmid, for example. The cloned
expression vector may then be transfected into the target

US 7,259,254 B2
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host cells and successfully transformed cells may be selected

The invention provides a set of biochemical and cellular
tools and assays that enable the user to identify to chemical

based on the presence of a suitable marker nucleic acid
sequence as described above.

compounds that are effective in activating or blocking

particular hormone-dependent regulatory pathWays in vari

DNA is commonly transferred or introduced into recipient
mammal or insect cells by calcium phosphate-mediated gene

ous organisms.
The invention relates to mutant nuclear hormone recep
tors that encode mutant nuclear hormone receptors, in Which
particular amino acid residues are substituted With respect to
Wild type, so as to be able to detect ligand binding to the

transfer, electroporation, lipofection, viral infection and the
like. General methods, vectors and general considerations
for gene transfer and expression may be found in M.

Kriegler, Gene Transfer and Expression: A Laboratory
Manual, Stockton Press (1990). Direct gene transfer to cells
in vivo is achieved by the use of modi?ed viral vectors,

mutant receptor by either a change in a physical property of

including retroviruses, adenoviruses, adeno-associated

nuclear hormone receptor construct. These proteins bind and
interact With ligands in substantially the same Way as their
Wild type counter part. HoWever, certain amino acid substi

the mutant receptor and/or an transcriptional induction of a

viruses and herpes viruses, liposomes, and direct injection of
DNA into certain cell types. See, e.g., Wilson, Nature, 365:
691-692 (1993); Plautz et al, Annals NY Acad. Sci., 716:
144-153 (1994); Farhood et al, Annals NYAcad. Sci., 716:
23-34 (1994) and Hyde et al Nature, 362: 250-255(1993).

tutions readily alloW changes in protein ?uorescence With
respect to Wild type facilitating the detection betWeen ligand
and receptor.
Another aspect of the invention relates to a method

Furthermore, cells may be transformed ex vivo selected as

identifying ligands of nuclear hormone receptors compris

described earlier and introduced directly at localized sites by

injection, e.g., intra-articular, intracutaneous, intramuscular

20

and the like.

This invention includes substantially identical polynucle
otides that hybridize under stringent conditions (as de?ned
herein) to all or a portion of the invention’s mutant receptor
sequences or hormone response element sequences (i.e.,

the transcriptional activity of the protein. Preferably, such a
method is scaled up and carried out by an apparatus capable
25

target sequences) or their complements. Under stringent

hybridization conditions, only highly complementary, i.e.,
substantially similar nucleic acid sequences, hybridize. Pref
erably, such conditions prevent hybridization of nucleic
acids having 4 or more mismatches out of 20 contiguous
nucleotides, more preferably 2 or more mismatches out of 20

ing: contacting a mutant nuclear hormone receptor protein
With a candidate ligand; and determining Whether there is a
change in a physical property of the protein or a change in

of simultaneously screening libraries of small molecules
generated by combinatorial chemistry or similar techniques
typical in the art.
Another aspect of the invention relates to a nucleic acids

30

that encode dominant negative mutant nuclear hormone
receptors. Preferably, dominant negative mutants are used to

interfere With endogenous nuclear hormone signaling path

contiguous nucleotides, most preferably one or more mis

Ways. Although the skilled artisan could envisage a multi

match out of 20 contiguous nucleotides. The hybridizing
portion of the hybridizing nucleic acid is at least about 80%,

tude of uses, preferably, such mutants are used in combina
tion With nuclear hormone receptor reporter construct to
control that a candidate ligand is binding an endogenous
nuclear hormone receptor and that this binding is the result
of in induction of the nuclear hormone receptor reporter
construct rather than some unforeseen independent mecha
nism.
Another aspect of the invention relates to a nuclear

preferably at least about 95%, or most preferably about at

35

least 98%, identical to the sequence of a portion or all of a

target sequence, or its complement.
Hybridization of a nucleic acid to a nucleic acid sample
under stringent conditions is de?ned beloW. Nucleic acid
duplex or hybrid stability is expressed as a melting tem

40

hormone receptor response element denoted by the formula
YDRXZ comprising a direct repeat (DR) comprising tWo
half sites separated by X nucleic acid bases; Wherein Z

perature (Tm), Which is the temperature at Which the probe
dissociates from the target DNA. This melting temperature
is used to de?ne the required stringency conditions. If
sequences are to be identi?ed that are substantially identical

to the probe, rather than identical, then it is useful to ?rst

45

indicates a forWard DR sequence of 5'-AGGTCA(N),CAG
GTCA-3' (SEQ ID NO: 8) and/or a reverse DR sequence of

establish the loWest temperature at Which only homologous

5'-TGACCT(N)xTGACCT-3' (SEQ ID NO: 9); Wherein the

hybridization occurs With a particular concentration of salt

element comprises at least one DR oriented in either a
forWard or reverse orientation; Wherein Y equals 1 to 8
forWard and/or reverse direct repeats; and X equals 1 to
about 12. Such elements may be operably linked to a Wide
variety of core or basal promoters to test nuclear hormone

(eg SSC or SSPE). Then assuming that 1% mismatching
results in a 1° C. decrease in Tm, the temperature of the ?nal

Wash in the hybridization reaction is reduced accordingly
(for example, if sequences having >95% identity With the
probe are sought, the ?nal Wash temperature is decrease by
50 C.). In practice, the change in Tm can be between 05° C.

50

receptor activation.

and 15° C. per 1% mismatch.

Stringent conditions involve hybridizing at 68° C. in
5><SSC/5>< Denhart’s solution/ 1.0% SDS, and Washing in

55

Wherein the hormone receptor response element denoted by
the formula YDRXZ comprises a direct repeat (DR) com

0.2><SSC/0.1% SDS at room temperature. Moderately strin
gent conditions include Washing in 3><SSC at 42° C. The
parameters of salt concentration and temperature be varied

to achieve optimal level of identity betWeen the primer and
the target nucleic acid. Additional guidance regarding such
conditions is readily available in the art, for example,
Sambrook, Fischer and Maniatis, Molecular Cloning, a

prising tWo half sites separated by X nucleic acid bases;
60

Sons (1994).

Wherein Z connotes a forWard DR sequence of 5'-AGGTCA

(N)xAGGTCA-3' (SEQ ID NO: 8) and/or a reverse DR

sequence of 5'-TGACCT(N)xTGACCT-3' (SEQ ID NO: 9);

laboratory manual, (2nd ed.), Cold Spring Harbor Labora
tory Press, NeW York, (1989) and F. M. Ausubel et al eds.,
Current Protocols in Molecular Biology, John Wiley and

Another aspect of the invention relates to nuclear hor
mone receptor reporter construct comprising a nuclear hor
mone receptor response element, a promoter and a reporter
nucleic acid sequence operably linked to one another;

65

Wherein the element comprises at least one DR oriented in
either a forWard or reverse orientation; Wherein Y equals 1
to 8 forWard and/or reverse direct repeats; and X equals 1 to

about 12; and Wherein the promoter is selected from the

group consisting of SEQ NOs: 3, 4, 5, and 6.

US 7,259,254 B2
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oligonucleotides Were (upper strand) for DR1: 5'-CAAG
GTCAAAGGTCAG-3' (SEQ ID NO: 13), for DR4:
5'-CAAGGTCAAGAAAGGTCAG-3' (SEQ ID NO: 14),

In another aspect of the invention, the set of tools and
assays disclosed herein are useful for screening for com

mercial compounds that Will have particular e?fects on the
function of USP/RXR receptors Will lead to the identi?ca
tion of environmentally safe, neW insecticides that are

for DR12: 5'-CAAGGTCAAGAAGGCCAAAGAGGT
CAG-3' (SEQ ID NO: 15; CTAG on 5' ends not shoWn). The
recovered YDRXCore constructs (X representing 1, 4 or 12

speci?c for disrupting the hormone receptor-dependent
physiological regulation of insects (pests of food/?ber/

intervening bases; Y representing the number of tandem
pairs of direct repeats) Were veri?ed by sequencing. The

ornamental plants, or vectors of disease agents) but not

disrupt the hormone receptor-dependent physiological regu

intervening sequences in the DR1 and DR4 motifs Were

lations of humans or other non-target vertebrates. These

randomly chosen, While the DR12 sequence used is found in
the ecdysteroid-sensitive ng-1 and ng-2 genes that are

assays could be designed in a ‘scaled up’ format, in Which
thousands of test chemicals are e?fectively assays for par

expressed during metamorphosis of D. melanogasler, and

ticular e?fects to disrupt the hormone receptor-dependent
regulation of insects.

can serve in vitro as a binding site for the various receptor

dimers involving USP (ecdysteroid receptor (EcR)/USP
heterodimer, USP/DHR38 heterodimer and USP/USP
homodimer.

EXAMPLE 1

Placement of four tandem copies of a DR12 motif

(CAAGGTCANNNNNNNNNNNNAGGTCAG SEQ ID

Cell Culture and Transfections

Spodoplera?’ugiperda cell line, Sf9, Was maintained and
transfected as described previously Jones et al (1998) Bio
chem. J. 335, 79-84; Jones et al. (2000) Biochem. J. 346,

20

fected Sf9 cells With methyl epoxyfarnesoate (FIG. 1B). In

233-240. As an internal control to compare activities of
different constructs, 0.3 pg of a constituitive heat-shock

promoter-driven [3-galactosidase gene Was cotransfected. To
study the role of USP in activation of the nuclear hormone
receptor response element fused to core promoter in methyl

contrast, insertion of a cassette containing four tandem
copies of either a DR1 or DR4 motif yielded only a 2.5- and
25

inserted DR12 cassette itself, and Was not due to either

insertional disruption or creation of a putative cryptic regu
latory element at the vector multiple cloning site. Due to the

the ligand-binding pocket Were cotransfected With the
reporter and internal control plasmids. At 36 h after the
transfection, the cells Were treated With 75 um methyl

highest reporter activity being obtained With the DR12
motif, We focussed on the DR12 repeat construct, toWards

epoxyfamesoate (Sigma) in ethanol carrier (1% ?nal ethanol
concentration) or just ethanol carrier only (previous studies

Fullerton, Calif.). [3-Galactosidase activity Was measured

using chlorophenol red-0t-d-galactopyranoside monosodium

3.5-fold induction, respectively (FIG. 1B). This dilferential
result con?rms that the 10-fold activation observed With the
4DR12Core construct Was caused by the sequence of the

epoxyfamesoate-treated cells, cloned D. melangasler USP
(dUSP) cDNA and its derivatives containing mutations in

demonstrated methyl epoxyfamesoate e?fects Were dose
dependent, With maximum near 75 pm). After 48 h of the
treatment, the cells Were harvested and the activity of the
luciferase reporter Was measured using a luciferase assay kit
(Promega) in a multipurpose scintillation counter (Beckman,

NO: 16), FIG. 1A) at 5' to the Core promoter reporter
(4DR12Core construct, FIG. 1B) yielded a 10-fold induction
in promoter activity in response to treatment of the trans

the goal of the study of ligand activation of USP.
35

We then con?rmed that sequences in the AGGTCA half
sites themselves of the DR12 motif Were necessary for

transducing the methyl epoxyfarnesoate signalling. We took
advantage of the previous report that mutation of each half
site abrogated the ability of DR12 motif to enhance ecdys
teroid transcriptional activation D’Avino et al. (1995) Mol.
40

(CPRG; Roche Molecular Biochemicals) as a colorimetric
substrate.

Cell. Endo. 113, 1-9. When We mutated here each half site
of the DR12 motif (in a construct containing a single DR12

in order to simplify mutational analysis; 1DR12mutCore),
the responsiveness of the 1DR12mutCore to methyl epoxy
famesoate Was no greater than the background of a Core

EXAMPLE 2
45

Nuclear Hormone Receptor Response Elements

Wild-type DR12 (1DR12Core, FIG. 2B).

The sequences and characteristics of the core promoter
(61 to +28) of the JHE gene Were described by Jones et al.

(2001) Insect Biochem. Mol. Biol. 32, 33-49; Jones et al
(1998) Biochem. J. 335, 79-84; 79-84; Jones et al. (2000)
Biochem. J. 346, 233-240. The core promoter responds to

EXAMPLE 3
50

Nuclear Extracts and Electrophoretic Mobility Shift Assay

respond to methyl epoxyfamesoate through a heterologous
5' ?anking direct repeat motif in cell transfection assay. This
Core promoter reporter Was cloned into KpnI/BglII sites of
pGL3. An NheI site Was then placed immediately 5' to the

Nuclear extracts Were isolated from Sf9 cells as previ
55

KpnI site, and multiple direct repeat (DR) sequences Were
cloned into the NheI site by the folloWing method. Comple

mentary oligonucleotides encoding the particular DR motif
Were synthesiZed, With each oligonucleotide possessing at

ously described Jones et al. (2001) Insect Biochem. Mol.
Biol. 32, 33-49; Jones et al (1998) Biochem. J. 335, 79-84;
79-84; Jones et al. (2000) Biochem. J. 346, 233-240. For the
DR12 probe, the double stranded DR12 oligonucleotide
(sequence as shoWn above) Was 5' end-labelled With 32P by

T4 polynucleotide kinase (NeW England Biolabs Inc.), and
60

its 5' end a four base overhang of an NheI restriction site

then puri?ed from a 20% native polyacrylamide gel. The
same double stranded DR12 oligonucleotide Was used in
100-fold excess as a self competitor. For the 4DR12Core
probe, the 4DR12Core sequence Was liberated from the
vector as a 148-bp ClaI/HindIII fragment, and Was 5' end

(CTAG). Upon annealing, the double stranded oligonucle
otides Would then have a CTAG overhang at each 5' end. The
annealed oligonucleotides Were then ligated into concatam

ers, fractionated by native PAGE and the gel fractions
corresponding to higher concatamer forms recovered and
ligated into the NheI site. Speci?c DR sequences for the

promoter With no enhancer (FIG. 2B); in contrast to the
responsiveness of the Core promoter in the presence of a

65

labelled With 32P and puri?ed. The same, unlabelled frag
ment Was used at 100-fold excess as a self competitor. As a

negative control for speci?city in gel shifts, the 36 bp

US 7,259,254 B2
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BglII/KpnI polylinker region fragment of the pGL3 vector

end of ot-helix

Was liberated and recovered from loW melting point agarose
gels and used as a 100 nonself competitor (sequence:

5'-CTTTCTCGAGCAGCTGGAGGCGtgG

12 With tryptophan residues

WaSZ

tgGCCACCCGGCCTGGCGATGAAACT-3' (SEQ ID NO:

GGTACCGAGCTCTTACGCGTGCTAGC
CCGGGCTCGA, SEQ ID NO: 17). Either a ?nal concen
tration of 500 nm of His-tagged Wild-type USP or His

21). All mutant constructs Were con?rmed by DNA sequenc
1ng.

tagged mutant Cys472Ala/His475Leu (=C472A/H475L),

length Wild-type and point-mutated dUSP coding sequences

or ?ve micrograms of nuclear proteins, Were incubated With

Were cloned into PmeI and NotI sites of the pIE1-4 vector

the given probe on ice for 30 min in binding buffer (10 mM
Tris/HCl, pH 7.5; 50 mM NaCl, 0.5 mM EDTA, 5%
glycerol, 1 mM MgCl2, and 1 mM dithiothreitol). In some
experiments, nuclear proteins Were preincubated With the
probe for 30 min folloWed by incubation With anti-USP mAb
(a gift from F. Kafatos, EMBL, Heidelberg), or monoclonal

(Novagen) and con?rmed by sequencing, and for bacterial
overexpression Were cloned into pET32EK (Novagen).

For expressing dUSP in Sf9 cells, PCR-generated full

EXAMPLE 5

Extraction of Total Proteins and Immunoblotting Analysis

Elav antibody (Developmental Studies Hybridoma Bank,

Total Sf9 cell protein extracts from transfected Sf9 cells

University of IoWa), for an additional 1 h on ice. Samples

Were fractionated by SDS/PAGE, 8% (W/v) polyacrylamide

Were then subjected to 4% (W/v) polyacrylamide gel elec
trophoresis in 0.5 Tris/borate/EDTA buffer. After electro
phoresis, the gels Were dried and exposed to Kodak ?lm at
70° C. for 12-48 h.
As an independent con?rmation of the important role of
the tWo direct repeat half sites in the DR12 motif, We
demonstrated that in a gel mobility shift assay With Sf9

nuclear extracts, the DR12 motif probe yielded a shifted
probe band that could be competed With excess, unlabelled
Wild-type DR12. HoWever, the same DR12 mutated in its
tWo half sites that had failed to support methyl epoxyfarne
soate-enhanced transcription in the cell transfection assay
also correspondingly failed to compete With the Wild-type

DR12 probe in the gel shift assay (FIG. 2A), con?rming the
functional necessity of the tWo half sites for interaction With
a nuclear component(s). Thus, the lack of binding to the
mutant DR12 combined With the lack of a transcriptional
effect of that same mutant DR12 indicates that the speci?c
binding to the Wild-type DR12 observed here relates to its

gel, and then transferred onto a nitrocellulose membrane.
USP Was detected using a primary USP AB11 monoclonal
20

(Bio-Rad). The USP signals Were normalized by an internal

control, [3-actin, Which Was detected by a primary polyclonal
[3-actin antibody (Sigma) and With an anti-rabbit IgG-AP
25

Puri?cation of the His-USP Fusion Protein and Ligand
30

binding Assay
The homodimer-enriched fraction of bacterial recombi

nant His-dUSP fusion protein Was puri?ed by nickel resin

selection, elution With imidaZole, centrifugal concentration,
and then gel permeation chromatography (Superdex 200)
35

ity shift assay using Sf9 nuclear extracts detected a single

With procedures and chemical sources exactly as already
described previously Jones et al. (2000) Insect Biochem.
Mol. Biol. 30, 671-679. The homodimer-enriched fraction of
the puri?ed His-USP fusion protein Was raised to 2 ml of
NaCl and a ?nal concentration of 0.5 pm. For a ?uores

40

to the DR12 probe (FIG. 2C). The speci?city of the AB11
monoclonal antibody effect on USP binding Was further
con?rmed in that no such effect Was produced by a negative

control monoclonal antibody against the transcription factor

secondary Ig (Southern Biotechnology Associates, Inc.).
EXAMPLE 6

positive action to transduce the methyl epoxyfamesoate
signalling observed in the transfection assay. The gel mobil

major complex binding to the DR12 probe (FIG. 2C). An
anti-dUSP mAb (AB11, epitope on DNA binding domain)
displaced the endogenous USP in the major complex binding

antibody and With an anti-mouse IgG-AP secondary Ig
(Bio-Rad) by a BCIP/NBT color development solution

45

cence-based ligand-binding assay based on intrinsic tryp
tophan ?uorescence Jones et al. (2001) Insect Biochem.
Mol. Biol. 32, 33-49; Jones et al (1998) Biochem. J. 335,
79-84; 79-84; Jones et al. (2000) Biochem. J. 346, 233-240;
Jones et al (1997) Proc. Natl. Acad. Sci. USA 94, 13499
13503, ligand or ethanol carrier Was added and the receptor
preparation excited at 290 nm and monitored for emission at

Elav.

340 nm, until the signal from the receptor had stabiliZed.
Fluorescence Was measured three times for each sample,

EXAMPLE 4
50

USP Mutants

replicated on three or more independent occasions, each
time With similar results.

Point mutations in the ligand-binding domain of dUSP
Were made With a ChameleonTM double-stranded site-di

rected mutagenesis kit (Stratagene) according to the manu
facturer’s instructions. The selection primer used to change
the unique NdeI (underlined) site in the pIE1-4 vector Was

With standard deviation typically smaller than the graphical
plotted datum point. Each ?uorescence experiment Was

55

CGGTATTTCACACCG

His-tagged dUSP dominant negative double mutant
Cys472Ala/His475Leu (C472A/H475L) Was over expressed
in methyl epoxyfamesoate-treated Sf9 cells that Were
cotransfected With the 4DR12Core reporter plasmid. Cells
transfected With either empty pIE1-4 vector, or that vector

CAcATGGTGCACTCTCAGTACAATC (SEQ ID NO: 18).

expressing Wild-type dUSP, responded to methyl epoxyfar

The primer to mutate Q288 to alanine in the ligand-binding

nesoate application With a similar induction of the

pocket

Was:

GTGCCAAGTGGTCAACAAA

60

primer that targeted tWo amino acids Was used to make the
double mutation in C473A and H476L because of their

activation observed for cells transfected With either the

adjacent locations, With the sequence: GCGATCGAT

CAGCCTGAAGgQCAGGAT
@CTGTTCCTCTTCCGCATTAC (SEQ ID NO: 20). A
primer that replaced tWo proline residues (P498, P499) at the

4DR12Core promoter (FIG. 4A). HoWever, cells transfected
With the plasmid expressing the C472A/H475L mutant
exhibited a distinct suppression in the level of methyl
epoxyfarnesoate-induced activation, as compared With the

g?CTCTTCCAGATGGTCGAATAC (SEQ ID NO: 19). A
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empty plasmid or plasmid expressing Wild-type dUSP (FIG.
4A). In addition, cotransfection of the empty vector, or
vector expressing either Wild-type dUSP or the C472A/

US 7,259,254 B2
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H475L mutant, did not affect the basal activation exhibited
When the Core promoter Without DR12 motifs Was used.

famesoate Was tested. In a ligand-binding assay that detects

methyl epoxyfamesoate binding through its e?fects to sup

Together, these data demonstrate that the suppression in
methyl epoxyfarnesoate-induced activation caused by over
expression of the C472A/H475L double mutant Was not due

press intrinsic ?uorescence of dUSP, Jones et al., (1998)
Biochem. J. 335, 79-84., Jones et al. (1997) Proc. Natl.
Acad. Sci. USA 94, 13499-13503, the bacterially overex

to nonspeci?c titration of coactivators required by a receptor
other than USP and not due to disruption of Core-binding

pressed His-tagged Wild-type dUSP indeed exhibited sup
pressed the ?uorescence due to the binding of methyl

basal transcription components independent of action
through the DR12 enhancer. In addition, overexpression of

mutant dUSP did not exhibit a signi?cant response to

epoxyfarnesoate (FIG. 5B). HoWever, the C472A/H475L

either the C472A/H475L double mutant or the Wild-type

epoxymethyl farnsoate (FIG. 5B). This result Was repro
duced With independent preparations of the Wild-type dUSP

dUSP did not change the level of endogenous USP (FIG.
4A), con?rming that overexpression of exogenous dUSP did

and C472/H475L dUSP. These results indicate that C472A/

not indirectly a?fect the methyl epoxyfamesoate-activation

H475L behaves as a dominant negative mutant in the

pathWay by disruption of endogenous USP expression.

pathWay for methyl epoxyfamesoate activation of the

Under the model that overexpression of the C472A/
H475L double mutant competed With endogenous USP in
the pathWays for transduction of the exogenous methyl
epoxyfamesoate signal, the level of e?fect of the double

4DRl2Core promoter and that the activity is due to the e?fect
of the C472A/H475L mutations on the ligand-binding activ

ity of USP.

mutant ought to be dependent on its dose. Indeed, a pro

gressive increase in the intracellular concentration of this

EXAMPLE 8
20

double mutant (With endogenous USP level remaining
USP Mutants With Altered Fluorescence
Some models of nuclear hormone receptor action postu

unchanged) caused progressive suppression in the methyl
epoxyfamesoate-activation of the DRl2Core promoter,
doWn to the transcriptional level observed for the Core

promoter Without DR12 enhancers (FIG. 4B). Over the
range of the progressive suppression of the methyl epoxy

25

movement of ot-helix 12 to a neW position, SteinmetZ et al

farnesoate-activated transcription there Was no e?fect of the
double mutant on the basal level of transcription in EtOH

treated controls. This background of the blocked activation
pathWay Was used to test Whether activation by methyl
epoxyfamesoate treatment Was actually dependent on the
presence of Wild-type USP. As shoWn in FIG. 4C, the

30

activation of the 4DRl2Core promoter in methyl epoxyfar
35

methyl epoxyfarnesoate-activated transcription, there Was
no e?fect of the transfected Wild-type dUSP on the basal level

of transcription in EtOH-treated controls.
The ability of the C472A/H475L mutant to bind DNA and

40

tions to the ligand-binding pocket did not generally deform
receptor structure. As shoWn in FIG. 5A, under electro

phoretic mobility shift assay conditions, both the Wild-type
45
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(on ot-helix 5) upon binding of methyl epoxyfarnesoate.
Alternatively, if ot-helix 12 does move in position upon

binding of methyl epoxyfamesoate, then the change in the

the DNA-binding domain). The similar DNA binding and
homodimeriZation capacities of the Wild-type dUSP and

local environment of the tWo added tryptophan residues on
ot-helix 12 may change their ?uorescence in a Way that

mutant C472A/H475L dUSP is strongly indicative that the
55

domain that are outside of the ligand-binding pocket, are in
a functionally similar conformation for both the Wild-type
and mutant receptors. Thus, any di?ference detected in

ligand binding of the tWo receptors is most reasonably
inferred as arising from di?erences in the architecture inside

move in position, their level of ?uorescence Would not

Would not enhance or disguise the suppression in ?uores
cence exhibited by the tWo other natural tryptophan residues

steroid receptor superfamily members is primarily due to

DNA-binding domain, and the parts of the ligand-binding

the four continuous proline residues at the end of ot-helix 12
With tryptophan residues, Was tested. Under the model that
USP ot-helix 12 does not move upon binding of methyl

change upon binding of methyl epoxyfamesoate into the
pocket. Therefore, their constant background ?uorescence

as homodimer. The homodimeriZation of RXR and other

contacts in the ligand-binding domain that are outside of the
ligand-binding pocket (in addition to some contacts also in

present Billas et al. (2000) J. Biol. Chem. 276, 7465-7474;
Jones et al (1997) Proc. Natl. Acad. Sci. USA 94, 13499
13503. Therefore, the hypothesis that ot-helix 12 is so ?rmly
locked in position that it does not move, by replacing tWo of

epoxyfarnesoate in the ligand-binding pocket, these tWo
tryptophan residues Would only raise the constant back
ground intrinsic ?uorescence of the receptor, but, on account
of the fact that they (as part of the ?xed ot-helix 12) do not

to homodimeriZe to con?rm Was examined that the muta

dUSP and the C472A/H475L mutant dUSP similarly bound
to a DR12 motif. In addition, both receptor preparations
bound to the probe similarly in part as monomer and in part

(2001) Annu. Rev. Biophys. Biomol. Struct. 30, 329-359.
HoWever, the tWo published crystal structures of USP in
complex With a phospholipid located at the opening of the
ligand-binding pocket shoW ot-helix 12 in a position that the
investigators described as so ?rmly ‘locked’ against other
residues of the ligand-binding domain that ot-helix 12 Would
not be able to move even if the phospholipid Were not

nesoate-treated cells Was monotonically restored in a man

ner dependent on the increasing dose of the added Wild-type
dUSP. Again, over the range of the monotonic restoration of

late that binding of ligand to the ligand-binding pocket
induces a tertiary conformational change involving the

yields a markedly di?ferent overall ?uorescence pattern for
the receptor. Indeed, as FIG. 6B shoWs, in this test the
Wild-type USP With only tWo natural tryptophan resides on
ot-helix 5 exhibits a distinct suppression in ?uorescence

upon binding of methyl epoxyfarnesoate. In contrast, the
60

mutant USP containing tWo additional tryptophan residues

the cavity of the ligand-binding pocket due to the C472A/
H475L point mutations.

instead sharply increasing in ?uorescence before then

EXAMPLE 7

patterns of ?uorescent response are most easily explained by

at the end of -helix 12 shoWed a much di?ferent pro?le,

decreasing (Panel C). Collectively, these markedly di?ferent
65

The ability of the Wild-type dUSP and dominant negative,
ligand-binding pocket mutant dUSP to bind methyl epoxy

a model in Which -helix 12 does move in relative position,

upon the binding of methyl epoxyfarnesoate into the ligand
binding pocket of USP.

